Spots Global Cancer Trial Database for gallbladder adenocarcinoma
Every month we try and update this database with for gallbladder adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels | NCT04931420 | Metastatic Canc... Foregut Carcino... Gastric Adenoca... Gallbladder Ade... Liver Cancer GI Cancer GI Carcinoma Lung Cancer | Standard of Car... Video-Assisted ... Lobectomy Consolidative R... Ablation Treatm... Resection or Ex... Peritonectomy Transarterial R... | 18 Years - | University of Chicago | |
| Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | NCT03267940 | Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Gallbladder Ade... | PEGPH20 CIS GEM Atezolizumab | 18 Years - | Halozyme Therapeutics | |
| Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer | NCT00361231 | Biliary Tract C... Gallbladder Ade... | Bevacizumab Gemcitabine Oxaliplatin | 18 Years - | Massachusetts General Hospital | |
| Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | NCT03267940 | Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Gallbladder Ade... | PEGPH20 CIS GEM Atezolizumab | 18 Years - | Halozyme Therapeutics | |
| Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma | NCT01093222 | Extrahepatic Bi... Gallbladder Ade... Gallbladder Ade... Hilar Cholangio... Recurrent Extra... Recurrent Gallb... Undifferentiate... Unresectable Ex... Unresectable Ga... | Erlotinib Hydro... Sorafenib Tosyl... | 18 Years - | National Cancer Institute (NCI) | |
| Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer | NCT00142480 | Biliary Tract C... Gallbladder Ade... | Capecitabine Oxaliplatin Bevacizumab Radiation thera... | 18 Years - | Massachusetts General Hospital | |
| Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer | NCT00142480 | Biliary Tract C... Gallbladder Ade... | Capecitabine Oxaliplatin Bevacizumab Radiation thera... | 18 Years - | Massachusetts General Hospital | |
| Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma | NCT01093222 | Extrahepatic Bi... Gallbladder Ade... Gallbladder Ade... Hilar Cholangio... Recurrent Extra... Recurrent Gallb... Undifferentiate... Unresectable Ex... Unresectable Ga... | Erlotinib Hydro... Sorafenib Tosyl... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
